Bioventix Plc Director/PDMR Shareholding

 
TIDMBVXP 
 
Bioventix plc 
 
                        ("Bioventix" or the "Company") 
 
                          Director/PDMR Shareholding 
 
Bioventix plc (BVXP), a UK company specialising in the development and 
commercial supply of high-affinity monoclonal antibodies for application in 
clinical diagnostics, was notified on 19 October 2017 of the following 
transactions in its ordinary shares of 5 pence each ("Ordinary Shares"): 
 
Director                Position        Ordinary  Sale price     Ordinary   Percentage 
                                          Shares         per  Shares held    of issued 
                                            sold    Ordinary subsequently        share 
                                                       Share              capital held 
                                                                          subsequently 
 
Ian Nicholson and       Non-Executive      5,000    2400.75p       18,000         0.4% 
Persons Closely         Chairman 
Associated 
 
Peter Harrison and      CEO               80,000    2425.00p      428,176         8.3% 
Persons Closely 
Associated 
 
   Notification and public disclosure of transactions by persons discharging 
     managerial responsibilities and persons closely associated with them 
 
         Details of the person discharging managerial responsibilities / 
         person closely associated 
 
a)       Names                   Ian Nicholson (Non-Executive Chairman) 
                                 Catherine Nicholson (PCA with Ian Nicholson) 
                                 Peter Harrison (CEO) 
 
         Reason for the Notification 
 
a)       Position/status         See 1(a) above, all are PDMR's or PCA's of 
                                 PDMR's 
 
b)       Initial notification/   Initial notification 
         Amendment 
 
         Details of the issuer, emission allowance market participant, auction 
         platform, auctioneer or auction monitor 
 
a)       Name                    Bioventix plc 
 
b)       LEI                     213800225MHX7LZQY108 
 
         Details of the transaction(s): section to be repeated for (i) each 
         type of instrument; (ii) each type of transaction; (iii) each date; 
         and (iv) each place where transactions have been conducted 
 
a)       Description of the      Ordinary shares of 5 pence ("Ordinary 
         Financial instrument,   Shares") 
         type of instrument 
 
         Identification code     GB00B4QVDF07 
 
b)       Nature of the           In each case, sale of Ordinary Shares 
         transaction 
 
c)       Price(s) and volume(s)  Ian Nicholson: 
 
                                 Price(s)              Volume(s) 
 
                                 2400.75p              2,500 
 
                                 Catherine Nicholson: 
 
                                 Price(s)              Volume(s) 
 
                                 2400.75p              2,500 
 
                                 Peter Harrison: 
 
                                 Price(s)              Volume(s) 
 
                                 2425.00p              80,000 
 
d)       Aggregated information: See 4(c) 
 
e)       Date of the transaction 19 October 2017 
 
f)       Place of the            London Stock Exchange, AIM Market (XLON) 
         transaction 
 
For further information please contact: 
 
Bioventix plc                                     Tel: [phone] 
Peter Harrison           Chief Executive Officer 
 
finnCap Ltd                                       Tel: [phone] 
Geoff Nash/Simon Hicks   Corporate Finance 
Stephen Norcross         Corporate Broking 
 
About Bioventix plc: 
 
Bioventix (www.bioventix.com) specialises in the development and commercial 
supply of high-affinity monoclonal antibodies with a primary focus on their 
application in clinical diagnostics, such as in automated immunoassays used in 
blood testing. The antibodies created at Bioventix are generated in sheep and 
are of particular benefit where the target is present at low concentration and 
where conventional monoclonal or polyclonal antibodies have failed to produce a 
suitable reagent. Bioventix currently offers a portfolio of antibodies to 
customers for both commercial use and R&D purposes, for the diagnosis or 
monitoring of a broad range of conditions, including heart disease, cancer, 
fertility, thyroid function and drug abuse. Bioventix currently supplies 
antibody products and services to the majority of multinational clinical 
diagnostics companies. Bioventix is based in Farnham, UK and its shares are 
traded on AIM under the symbol BVXP. 
 
 
 
END 
 

(END) Dow Jones Newswires

October 20, 2017 05:09 ET (09:09 GMT)